FDA panel rejects EDAP's cancer treatment

A Food and Drug Administration advisory committee voted against approval for EDAP TMS's (Nasdaq: EDAP) prostate cancer treatment Ablatherm-HIFU device sending the stock price plummeting $1.49 to $1.93.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.